Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.

Objective: This study aims to determine the effectiveness of converting patients from high doses of full-opioid agonists to sublingual (SL) buprenorphine.

Design: An observational report of outcomes assessment.

Setting: An interventional pain management practice setting in the United States.

Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.

Background: Sublingual buprenorphine-naloxone (buprenorphine SL) is a preparation that is used to treat opioid dependence. In addition, the Drug Enforcement Administration (DEA) has acknowledged the legality of an off-label use to treat pain with a sublingual buprenorphine preparation. Buprenorphine SL is unique among the opioid class of analgesics; this compound has a high affinity for the mu-receptor, yet only partially activates it.

Percutaneous sacroplasty for osteoporotic sacral insufficiency fractures: a prospective, multicenter, observational pilot study.

Background Context: Sacral insufficiency fractures (SIFs) can cause low back pain in osteoporotic patients. Symptomatic improvement may require up to 12 months. Treatment includes limited weightbearing and bed rest, oral analgesics, and sacral corsets.

Efficacy and safety of percutaneous sacroplasty for painful osteoporotic sacral insufficiency fractures: a prospective, multicenter trial.

Study Design: A prospective observational cohort study of consecutive osteoporotic patients with sacral insufficiency fractures (SIFs).

Objective: Assess the safety and efficacy of sacroplasty in treating osteoporotic SIFs.

Summary Of Background Data: SIFs can cause low back pain in osteoporotic patients.